Actelion Ltd. Launches VALCHLOR (Mechlorethamine) Gel 0.016% In The U.S.

Published: Nov 18, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Actelion (SIX: ATLN) announced today that VALCHLORâ„¢ (mechlorethamine), the first and only FDA-approved topical formulation of mechlorethamine, is now available for patients in the United States (US). VALCHLOR, a gel which is applied topically once a day, is an alkylating drug indicated to treat patients with stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) who have received prior skin-directed therapy. VALCHLOR is an orphan drug that was acquired by Actelion US Holding Company, a subsidiary of Actelion Ltd., on September 18, 2013 as part of a merger with Ceptaris Therapeutics, Inc. VALCHLOR is distributed in the US by Accredo Specialty Pharmacy.

Help employers find you! Check out all the jobs and post your resume.

Back to news